Trial Profile
Molecular Profiling of Advanced Soft-tissue Sarcomas. A Phase III Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Capmatinib (Primary) ; Ceritinib (Primary) ; Dabrafenib (Primary) ; Durvalumab (Primary) ; Futibatinib (Primary) ; Glasdegib (Primary) ; Lapatinib (Primary) ; Nilotinib (Primary) ; Olaparib (Primary) ; Palbociclib (Primary) ; Trametinib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms MULTISARC
- 05 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 04 Oct 2022 Planned End Date changed from 1 Oct 2024 to 1 Oct 2025.
- 04 Oct 2022 Planned primary completion date changed from 1 Oct 2022 to 1 Oct 2023.